Biotie Therapies IPO Info

Company Name: Biotie Therapies
Stock Symbol: BITI
Exchange: NASDAQ
Status: Priced
IPO Date: 6/11/2015
IPO Price: 14.88 (-3.56%)
Underwriters
RBC Capital, Stifel, JMP Securities, Roth Capital

Amount of Offering: N/A
Number of Shares Offered: 3.761 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner Lundbeck. The current development products include tozadenant for Parkinson's disease, which is transitioning into Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver.

SEC Filings

News Headlines